Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment (CagriSema) on Appetite and Functional Brain Activity in People With Overweight or Obesity

NCT06267092 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06267092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06267092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment (CagriSema) on Appetite and Functional Brain Activity in People With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
February 15, 2024
Completion date
December 8, 2025
Enrollment
164 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight